TY - JOUR
T1 - Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Cambridge, UK, 7–8 April 2022
AU - Mosbah, Héléna
AU - Akinci, Baris
AU - Araújo-Vilar, David
AU - Carrion Tudela, Juan
AU - Ceccarini, Giovanni
AU - Collas, Philippe
AU - Farooqi, I. Sadaf
AU - Fernández-Pombo, Antía
AU - Jéru, Isabelle
AU - Karpe, Fredrik
AU - Krause, Kerstin
AU - Maffei, Margherita
AU - Miehle, Konstanze
AU - Oral, Elif
AU - Perez de Tudela, Naca
AU - Prieur, Xavier
AU - Rochford, Justin
AU - Sanders, Rebecca
AU - Santini, Ferruccio
AU - Savage, David B.
AU - von Schnurbein, Julia
AU - Semple, Robert
AU - Stears, Anna
AU - Sorkina, Ekaterina
AU - Vantyghem, Marie Christine
AU - Vatier, Camille
AU - Vidal-Puig, Antonio
AU - Vigouroux, Corinne
AU - Wabitsch, Martin
N1 - Funding Information:
The ECLip members are very grateful to the editor in chief Pr Castinetti for his support in the publication of this manuscript. The Center for Rare Endocrine Diseases at the University of Ulm, the Obesity and Lipodystrophy Center at the University Hospital of Pisa, the French Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity, the Unit of Lipodystrophies, Division of Endocrinology and Nutrition at the Clinical University Hospital of Santiago de Compostela, Spain, and and the Federal State Budgetary Institution “National Medical Research Centre of Endocrinology” of the Ministry of Health of Russian Federation are part of the European Consortium of Lipodystrophies. The Obesity and Lipodystrophy Center at the University Hospital of Pisa, Italy is part of the European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN-Project ID No 739543). The Center for Rare Endocrine Diseases at the University of Ulm, Deutschland, the Obesity and Lipodystrophy Center at the University Hospital of Pisa, Italy, the French Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity are part of the European Reference Network for Rare Endocrine Conditions (EndoERN Project ID No 739572). EndoERN is co-funded by the European Union within the framework of the 3rd Health Program. EndoERN is supported by the European Society of Endocrinology and the European Society for Pediatric Endocrinology. David B Savage was supported by the Wellcome Trust (grant number WT 219417).
PY - 2022/12/12
Y1 - 2022/12/12
N2 - Eclip Meeting ProceedingsLipodystrophy syndromes are rare diseases with defects in the development or maintenance of adipose tissue, frequently leading to severe metabolic complications. They may be genetic or acquired, with variable clinical forms, and are largely underdiagnosed. The European Consortium of Lipodystrophies, ECLip, is a fully functional non-profit network of European centers of excellence working in the field of lipodystrophies. It provides a favorable environment to promote large Europe-wide and international collaborations to increase the basic scientific understanding and clinical management of these diseases. It works with patient advocacy groups to increase public awareness. The network also promotes a European Patient Registry of lipodystrophies, as a collaborative research platform for consortium members. The annual congress organized gives an update of the findings of network research groups, highlighting clinical and fundamental aspects. The talks presented during the meeting in Cambridge, UK, in 2022 are summarized in these minutes.
AB - Eclip Meeting ProceedingsLipodystrophy syndromes are rare diseases with defects in the development or maintenance of adipose tissue, frequently leading to severe metabolic complications. They may be genetic or acquired, with variable clinical forms, and are largely underdiagnosed. The European Consortium of Lipodystrophies, ECLip, is a fully functional non-profit network of European centers of excellence working in the field of lipodystrophies. It provides a favorable environment to promote large Europe-wide and international collaborations to increase the basic scientific understanding and clinical management of these diseases. It works with patient advocacy groups to increase public awareness. The network also promotes a European Patient Registry of lipodystrophies, as a collaborative research platform for consortium members. The annual congress organized gives an update of the findings of network research groups, highlighting clinical and fundamental aspects. The talks presented during the meeting in Cambridge, UK, in 2022 are summarized in these minutes.
KW - Antibody
KW - Caveolin-1
KW - Encephalopathy
KW - EPHX1
KW - Fatty acid
KW - Lipodystrophy syndrome
KW - Metreleptin
KW - miRNA
KW - Registry
KW - Seipin
KW - Therapeutic education
KW - Total body irradiation
UR - http://www.scopus.com/inward/record.url?scp=85141531939&partnerID=8YFLogxK
U2 - 10.1016/j.ando.2022.07.674
DO - 10.1016/j.ando.2022.07.674
M3 - Editorial
C2 - 36206842
AN - SCOPUS:85141531939
VL - 83
SP - 461
EP - 468
JO - Annales d'Endocrinologie
JF - Annales d'Endocrinologie
SN - 0003-4266
IS - 6
ER -
